BRPI0311233B8 - métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra - Google Patents
métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostraInfo
- Publication number
- BRPI0311233B8 BRPI0311233B8 BRPI0311233A BRPI0311233A BRPI0311233B8 BR PI0311233 B8 BRPI0311233 B8 BR PI0311233B8 BR PI0311233 A BRPI0311233 A BR PI0311233A BR PI0311233 A BRPI0311233 A BR PI0311233A BR PI0311233 B8 BRPI0311233 B8 BR PI0311233B8
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- hcc
- gpc3
- screening
- determining
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
diagnóstico de carcinoma hepatocelular a invenção refere-se a um método para triar um paciente para hcc, determinando o nível de glipicano (gpc3) em uma amostra de fluido corporal do paciente. é proporcionado um método adicional para diagnosticar hcc .por meio da detecção de gpc3 em uma amostra de tecido hepático. também são proporcionados anticorpos os quais ligam especificamente ao gpc3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38234002P | 2002-05-23 | 2002-05-23 | |
| US60/382,340 | 2002-05-23 | ||
| PCT/CA2003/000752 WO2003100429A2 (en) | 2002-05-23 | 2003-05-22 | Diagnosis of hepatocellular carcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0311233A2 BRPI0311233A2 (pt) | 2016-06-28 |
| BRPI0311233B1 BRPI0311233B1 (pt) | 2019-08-13 |
| BRPI0311233B8 true BRPI0311233B8 (pt) | 2021-07-27 |
Family
ID=29584393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0311233A BRPI0311233B8 (pt) | 2002-05-23 | 2003-05-22 | métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7883853B2 (pt) |
| EP (1) | EP1506406B1 (pt) |
| JP (1) | JP4455324B2 (pt) |
| CN (1) | CN100401068C (pt) |
| AT (1) | ATE425461T1 (pt) |
| AU (1) | AU2003229191B2 (pt) |
| BR (1) | BRPI0311233B8 (pt) |
| CA (1) | CA2482881C (pt) |
| DE (1) | DE60326567D1 (pt) |
| ES (1) | ES2324029T3 (pt) |
| IL (1) | IL164848A0 (pt) |
| MX (1) | MXPA04011132A (pt) |
| NZ (1) | NZ536521A (pt) |
| PT (1) | PT1506406E (pt) |
| RU (1) | RU2319969C2 (pt) |
| WO (1) | WO2003100429A2 (pt) |
| ZA (1) | ZA200410077B (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドに対する抗体 |
| AU2002330482A1 (en) | 2002-09-04 | 2004-03-29 | Perseus Proteomics Inc. | Method of diagnosing cancer by detecting gpc3 |
| WO2004022595A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | MRL/lprマウスを用いた抗体の作製 |
| US7303914B2 (en) * | 2003-01-30 | 2007-12-04 | Hongyang Wang | Monoclonal antibody against human hepatoma and use thereof |
| WO2005023301A1 (ja) * | 2003-09-04 | 2005-03-17 | Chugai Seiyaku Kabushiki Kaisha | 胆管癌治療剤および検出薬 |
| WO2005085861A2 (en) * | 2004-03-03 | 2005-09-15 | Oridis Biomed Forschungs- Und Entwicklungs Gmbh | Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer |
| EP1742061A4 (en) | 2004-04-28 | 2007-11-21 | Perseus Proteomics Inc | MEDIUM FOR PREDICTING AND EVALUATING THE REACTION OF LIVER CANCER AFTER TREATMENT |
| SI1674111T1 (sl) * | 2004-07-09 | 2011-02-28 | Chugai Pharmaceutical Co Ltd | Protitelo proti glipikanu 3 |
| JP4733042B2 (ja) * | 2004-08-24 | 2011-07-27 | 中外製薬株式会社 | 抗グリピカン3抗体を用いたアジュバント療法 |
| US20080003623A1 (en) * | 2004-10-05 | 2008-01-03 | Atsushi Nakajima | Monitoring Agent for Seriousness of Hepatitis |
| AU2005297772B2 (en) | 2004-10-26 | 2011-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| WO2007053659A2 (en) * | 2005-11-01 | 2007-05-10 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method of screening for hepatocellular carcinoma |
| BRPI0909672B1 (pt) * | 2008-03-17 | 2018-09-18 | Chugai Seiyaku Kabushiki Kaisha | método de imunoensaio in vitro para detecção da presença de células de câncer de fígado em um indivíduo, método para classificação de células de câncer de fígado presentes em um indivíduo, método in vitro para determinação de administrar ou não um agente anticâncer contendo um anticorpo anti-glipicano 3 a um indivíduo, e método in vitro para determinação de uma dose de um agente anticâncer contendo um anticorpo anti-glipicano 3 no tratamento de câncer de fígado em um indivíduo |
| CN101393217B (zh) * | 2008-09-27 | 2012-05-30 | 中国人民解放军第二军医大学 | 一种原发性肝癌血清标志物的检测试剂盒 |
| JP5439494B2 (ja) * | 2008-10-21 | 2014-03-12 | バイエル ヘルスケア エルエルシー | 肝細胞癌と関連するシグネチャ遺伝子の同定 |
| KR20100098324A (ko) * | 2009-02-27 | 2010-09-06 | 포항공과대학교 산학협력단 | Tm7sf3를 유효성분으로 함유하는 간암 진단용 조성물, 및 항 tm7sf3 항체를 유효성분으로 함유하는 간암 진단 키트, 및 간암 예방 또는 치료용 약학 조성물 |
| CN102356316B (zh) | 2009-03-05 | 2015-07-08 | 独立行政法人产业技术综合研究所 | 肝内胆管癌的检出、辨别方法 |
| CN102180969B (zh) * | 2011-01-30 | 2013-04-10 | 中国人民解放军军事医学科学院微生物流行病研究所 | 抗肝癌活性单克隆抗体及其应用 |
| CN102183660A (zh) * | 2011-03-09 | 2011-09-14 | 倪温慨 | 检测Glypican-3的时间分辨免疫荧光试剂盒 |
| CN102353791A (zh) * | 2011-06-30 | 2012-02-15 | 倪润洲 | 一种分离检测afp亚型的新方法 |
| EP3557260B1 (en) | 2012-12-21 | 2022-05-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
| TWI693073B (zh) * | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
| WO2014159087A1 (en) * | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma |
| CN105452865A (zh) * | 2013-08-06 | 2016-03-30 | 金弦起 | 小肝细胞癌和潜伏于肝硬化的肝细胞癌诊断用组合物 |
| EP3088890B1 (en) | 2013-12-24 | 2020-09-23 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring soluble gpc3 protein |
| JP6827319B2 (ja) | 2014-05-08 | 2021-02-10 | 中外製薬株式会社 | Gpc3標的治療剤療法が有効である患者に投与されるgpc3標的治療剤 |
| WO2015179658A2 (en) * | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| KR101704533B1 (ko) * | 2014-10-13 | 2017-02-09 | 경북대학교병원 | 간암 바이오마커로서의 ERRγ 및 이의 용도 |
| JP7096667B2 (ja) | 2015-07-01 | 2022-07-06 | 中外製薬株式会社 | Gpc3標的治療剤が有効である患者に投与されるgpc3標的治療剤 |
| ES2883240T3 (es) * | 2015-08-03 | 2021-12-07 | Cafa Therapeutics Ltd | Anticuerpo contra glipicano-3 y aplicación del mismo |
| JP6292564B2 (ja) * | 2016-03-10 | 2018-03-14 | シスメックス株式会社 | 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット |
| US11767362B1 (en) | 2016-03-15 | 2023-09-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies |
| WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT |
| AU2022388928A1 (en) | 2021-11-16 | 2024-05-16 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| CN114813266B (zh) * | 2022-03-15 | 2025-08-22 | 中国人民解放军海军军医大学第三附属医院 | 血液样本中gpc-3复合物的富集、检测方法及应用 |
| KR20260020412A (ko) | 2023-06-16 | 2026-02-11 | 살루브리스 (청두) 바이오테크 코., 리미티드 | 항-gpc3 항체 또는 항원 결합 단편 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU218175A (en) * | 1974-09-12 | 1984-04-30 | Schwartzhaupt Kg | Process for total or individual determination of lactate dehydrogenase isoenzyme |
| US5171850A (en) * | 1988-08-31 | 1992-12-15 | The Ontario Cancer Institute | Intestinal oncofetal gene |
| JP2946216B2 (ja) | 1989-07-12 | 1999-09-06 | 武田薬品工業株式会社 | 新規ハイブリドーマ,モノクローナル抗体および用途 |
| EP0477739A3 (en) | 1990-09-27 | 1992-12-09 | F. Hoffmann-La Roche Ag | Glycosyl-phosphatidylinositol-specific phospholipase d |
| AU2422999A (en) * | 1998-01-27 | 1999-08-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | New members of the glypican gene family |
| EP1146903A4 (en) * | 1998-10-16 | 2005-02-16 | Univ California | GLYPICANE FOR THE DETECTION AND TREATMENT OF HUMAN CARCINOMA |
| KR100953520B1 (ko) * | 2001-06-22 | 2010-04-21 | 츄가이 세이야꾸 가부시키가이샤 | 항글리피칸 3항체를 포함하는 항암제 |
-
2003
- 2003-05-22 MX MXPA04011132A patent/MXPA04011132A/es active IP Right Grant
- 2003-05-22 DE DE60326567T patent/DE60326567D1/de not_active Expired - Lifetime
- 2003-05-22 ES ES03724724T patent/ES2324029T3/es not_active Expired - Lifetime
- 2003-05-22 BR BRPI0311233A patent/BRPI0311233B8/pt not_active IP Right Cessation
- 2003-05-22 CA CA2482881A patent/CA2482881C/en not_active Expired - Lifetime
- 2003-05-22 PT PT03724724T patent/PT1506406E/pt unknown
- 2003-05-22 US US10/514,294 patent/US7883853B2/en not_active Expired - Lifetime
- 2003-05-22 JP JP2004507835A patent/JP4455324B2/ja not_active Expired - Lifetime
- 2003-05-22 WO PCT/CA2003/000752 patent/WO2003100429A2/en not_active Ceased
- 2003-05-22 IL IL16484803A patent/IL164848A0/xx not_active IP Right Cessation
- 2003-05-22 EP EP03724724A patent/EP1506406B1/en not_active Revoked
- 2003-05-22 RU RU2004136285/15A patent/RU2319969C2/ru active
- 2003-05-22 AT AT03724724T patent/ATE425461T1/de not_active IP Right Cessation
- 2003-05-22 NZ NZ536521A patent/NZ536521A/en not_active IP Right Cessation
- 2003-05-22 CN CNB038107910A patent/CN100401068C/zh not_active Expired - Lifetime
- 2003-05-22 AU AU2003229191A patent/AU2003229191B2/en not_active Expired
-
2004
- 2004-12-14 ZA ZA2004/10077A patent/ZA200410077B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1506406A2 (en) | 2005-02-16 |
| ATE425461T1 (de) | 2009-03-15 |
| ZA200410077B (en) | 2005-12-28 |
| CA2482881C (en) | 2016-11-08 |
| DE60326567D1 (de) | 2009-04-23 |
| PT1506406E (pt) | 2009-06-03 |
| MXPA04011132A (es) | 2005-08-15 |
| RU2004136285A (ru) | 2005-10-10 |
| RU2319969C2 (ru) | 2008-03-20 |
| BRPI0311233A2 (pt) | 2016-06-28 |
| CA2482881A1 (en) | 2003-12-04 |
| CN1653336A (zh) | 2005-08-10 |
| JP4455324B2 (ja) | 2010-04-21 |
| EP1506406B1 (en) | 2009-03-11 |
| HK1074251A1 (en) | 2005-11-04 |
| US7883853B2 (en) | 2011-02-08 |
| JP2005526979A (ja) | 2005-09-08 |
| WO2003100429A3 (en) | 2004-02-19 |
| AU2003229191A1 (en) | 2003-12-12 |
| BRPI0311233B1 (pt) | 2019-08-13 |
| US20050233392A1 (en) | 2005-10-20 |
| IL164848A0 (en) | 2005-12-18 |
| WO2003100429A2 (en) | 2003-12-04 |
| AU2003229191B2 (en) | 2009-07-30 |
| CN100401068C (zh) | 2008-07-09 |
| NZ536521A (en) | 2006-04-28 |
| ES2324029T3 (es) | 2009-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0311233B8 (pt) | métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra | |
| NZ601022A (en) | Diagnosis and treatment of cancer using anti-ereg antibody | |
| WO2006128192A3 (en) | Use of free circulating dna for diagnosis, prognosis, and treatment of cancer | |
| DE602006018578D1 (de) | Diagnose- und prognoseverfahren von blasenkrebs. | |
| Youns et al. | Serum talin-1 is a potential novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients | |
| BRPI0707645B8 (pt) | métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano | |
| ATE411525T1 (de) | Nachweis einer histonmodifikation in zellfreien nukleosomen | |
| BRPI0315666B8 (pt) | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos | |
| GB201209668D0 (en) | Methods of monitoring conditions by sequence analysis | |
| WO2007146668A3 (en) | Use of imp3 as a prognostic marker for cancer | |
| EP1838867A4 (en) | APOLIPOPROTEIN A II ISOFORM AS A BIOMARKER FOR PROSTATE CANCER | |
| WO2008012362A3 (en) | New protein isoforms and uses thereof | |
| WO2008014458A3 (en) | Protein markers for the diagnosis and prognosis of ovarian and breast cancer | |
| DE602006019262D1 (de) | QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN | |
| Zhang et al. | Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems | |
| RU2011144835A (ru) | Способы и композиции на основе белков для диагностики колоректальной аденокарциномы | |
| BRPI0712273A2 (pt) | Anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit | |
| DE60325382D1 (de) | Verfahren zur diagnose von gebärmutterhalskrebs | |
| WO2006133923A3 (en) | Diagnosis, prognosis and prediction of recurrence of breast cancer | |
| ATE545867T1 (de) | I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom | |
| BRPI0406265B8 (pt) | método para análise por eletroforese capilar, método para pesquisa e tipagem de proteínas monoclonais, método de preparação de anticorpos modificados sobrecarregados negativamente e kit para detecção e tipagem de proteínas monoclonais | |
| WO2003099107A3 (en) | Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient | |
| FR2930036B1 (fr) | Procede de diagnostic d'une hypertension arterielle pulmonaire. | |
| DK1095271T3 (da) | Fremgangsmåde til diagnose af hjertekar-sygdomme og tidlig aterosklerose | |
| BRPI0607016A2 (pt) | marcadores polipeptìdicos para o diagnóstico de cáncer de próstata |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/05/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |